📋 Sanofi And Regeneron : European Commission Approves Dupixent For CSU In Adults And Adolescents 완벽가이드
✨ Sanofi And Regeneron : European Commission Approves Dupixent For CSU In Adults And Adolescents
★ 56 전문 정보 ★
(RTTNews) – Sanofi (SNY, SNYNF, SAN.PA) and Regeneron Pharmaceuticals Inc. (REGN) announced that the European Commission has approved Dupixent (dupilumab) as a first-line targeted treatment for moderate-to-severe chronic spontaneous urticaria (CSU) in adults and adolescents aged
🎯 핵심 특징
✅ 고품질
검증된 정보만 제공
⚡ 빠른 업데이트
실시간 최신 정보
💎 상세 분석
전문가 수준 리뷰
📖 상세 정보
(RTTNews) – Sanofi (SNY, SNYNF, SAN.PA) and Regeneron Pharmaceuticals Inc. (REGN) announced that the European Commission has approved Dupixent (dupilumab) as a first-line targeted treatment for moderate-to-severe chronic spontaneous urticaria (CSU) in adults and adolescents aged